Identifcation of extracellular matrix-associated signatures to establish a risk model in rheumatoid arthritis and osteoarthritis through transcriptomic analysis.

BACKGROUND: Rheumatoid arthritis (RA) and osteoarthritis (OA) frequently coexist, complicating diagnosis and treatment. The extracellular matrix (ECM) serves as a critical modulator of disease progression, coordinating multilayered matrix degradation and inflammatory cascades in both conditions. This study aims to identify ECM-driven molecular signatures to stratify the risk of RA and OA. METHODS: We integrated bulk transcriptomics data from 113 samples across four datasets, as well as scRNA-seq data from 101 samples comprising 449,907 cells. Differential expression analysis, weighted gene co-expression network analysis, and machine learning were employed to identify ECM-related hub genes. A risk score (RS) model based on ridge regression was established and validated. The model was correlated with immune cell profiles, and a regulatory network involving miRNAs, mRNAs, transcription factors, and drugs was constructed. RESULTS: We identified eight ECM hub genes (SPARC, COL1A1, ANGPTL2, THY1, COL5A1, LRRC15, NID2, THBS3) that were significantly upregulated in RA and OA. The RS model stratified patients into high-risk and low-risk groups. The diagnostic performance of the model, as measured by AUC values, exceeded 0.8 across all cohorts. scRNA-seq and immune cell infiltration analyses revealed the involvement of these genes in ECM dysregulation. We predicted the relationship between genes and multiple factors, in which the drug Metoprolol was associated with LRRC15. CONCLUSIONS: We established an ECM-derived risk signature with robust diagnostic power, elucidating the shared mechanisms of ECM immune dysregulation. Metoprolol was associated with LRRC15 in the disease cohort. This study provides a framework for precise diagnosis and targeted therapy.